A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies

Inclusion Criteria:

- Patients with histologically/cytologically confirmed advanced solid tumors with FGFR1
or FGFR2 amplification or FGFR3 mutation, for which no further effective standard
anticancer treatment exists

- Adequate bone marrow function

- Adequate hepatic and renal function

- Adequate cardiovascular function

- Contraception.

- For women: Must be surgically sterile, post-menopausal, or compliant with a
medically approved contraceptive regimen during and for 3 months after the
treatment period; must have a negative serum or urine pregnancy test and must
not be nursing.

- For men: Must be surgically sterile or compliant with a contraceptive regimen
during and for 3 months after the treatment period

Exclusion Criteria:

- Patients with primary CNS tumor or CNS tumor involvement

- Patients with history and/or current evidence of endocrine alteration of
calcium-phosphate homeostasis

- History and/or current evidence of ectopic mineralization/ calcification including
but not limited to the soft tissue, kidneys, intestine, myocard and lung with the
exception of calcified lymphnodes and asymptomatic coronary calcification

- Current evidence of corneal disorder/ keratopathy incl. but not limited to bullous/
band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivitis
etc., confirmed by ophthalmologic examination.

- History or current evidence of cardiac arrhythmia and/or conduction abnormality

- Women who are pregnant or nursing.

Other protocol-defined inclusion/exclusion criteria may apply